Myriad Genetics (MYGN) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 4, 2026, to be held virtually, with voting rights for shareholders of record as of April 8, 2026.

• Strategic focus sharpened on the Cancer Care Continuum, with continued disciplined growth in Prenatal Health and Mental Health businesses.

• Leadership transitions in 2025 included new CEO, CFO, and Chief Commercial Officer appointments to drive profitable growth.

• 2025 revenue was $824.5 million, with positive adjusted EBITDA and adjusted EPS, despite headwinds from payer coverage changes and divestitures.

• Launches of new diagnostic tests, including Precise MRD for breast cancer, AI-enabled Prolaris for prostate cancer, and FirstGene prenatal screen, are expected in 2026.

Voting matters and shareholder proposals

• Election of three Class III Directors to serve until the 2029 Annual Meeting.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026.

• Advisory vote to approve executive compensation (Say-on-Pay).

• Approval of amendment to the 2012 Employee Stock Purchase Plan, increasing authorized shares by 4,000,000.

• Approval of the 2026 Employee, Director and Consultant Equity Incentive Plan, authorizing up to 8,568,431 shares.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of nine members, with eight independent directors and a separate Chair and CEO.

• Board diversity: 44% women and/or ethnically diverse; 33% of Board members are women.

• Annual Board and committee self-assessments and regular refreshment, with three new directors in the last five years.

• Robust stock ownership guidelines, majority voting in uncontested elections, and mandatory retirement age.